GeoVax Labs, Inc. has announced a series of executive changes effective in mid-November 2026. The company reported the resignation of Chief Financial Officer Mark W. Reynolds, who served as the principal financial and accounting officer, effective November 13, 2026.

On November 16, 2026, the Board of Directors appointed Anna Skowron as Chief Financial Officer. Ms. Skowron, 39, will also serve as the principal financial and accounting officer. She is designated by BPC Consulting Ltd. to perform these duties on a fractional basis. Under the CFO Consulting Agreement, Ms. Skowron oversees accounting and financial reporting, including the preparation of SEC filings. The company will pay BPC Consulting Ltd. $10,000 per month, plus applicable taxes, with a performance-based bonus available upon completion of the annual Form 10-K and year-end audit. Ms. Skowron holds a Bachelor of Commerce degree from the University of Toronto.

In a separate agreement dated November 5, 2026, the company appointed Tyler O’Brien as Interim Chief Executive Officer and Chairman of the Board. Mr. O’Brien serves as a non-employee consultant until a permanent principal executive officer is appointed. He receives $15,000 per month, subject to periodic review, and is eligible for incentive compensation and equity-based plans.

Additionally, the company terminated Kelly T. McKee, M.D., as Chief Medical Officer, effective November 17, 2026.